News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
70,832 Results
Type
Article (1647)
Company Profile (11)
Press Release (69173)
Section
Business (29692)
Career Advice (42)
Deals (4724)
Drug Delivery (1)
Drug Development (7961)
Employer Resources (9)
FDA (1395)
Job Trends (1889)
News (42078)
Policy (2347)
Tag
Academia (135)
Accelerated approval (6)
Allergies (17)
Alliances (2485)
ALS (9)
Alzheimer's disease (177)
Antibody-drug conjugate (ADC) (37)
Approvals (1507)
Artificial intelligence (23)
Autoimmune disease (27)
Automation (2)
Bankruptcy (13)
Best Places to Work (1867)
BIOSECURE Act (1)
Biosimilars (21)
Biotechnology (5)
Bladder cancer (48)
Brain cancer (3)
Breast cancer (123)
Cancer (713)
Cardiovascular disease (59)
Career advice (37)
Career pathing (1)
CAR-T (34)
Cell therapy (71)
Cervical cancer (4)
Clinical research (7657)
Collaboration (110)
Compensation (85)
Complete response letters (3)
COVID-19 (179)
CRISPR (9)
C-suite (36)
Cystic fibrosis (16)
Data (1121)
Depression (12)
Dermatology (13)
Diabetes (75)
Diagnostics (720)
Digital health (3)
Diversity, equity & inclusion (1)
Drug discovery (9)
Drug pricing (3)
Duchenne muscular dystrophy (19)
Earnings (28063)
Editorial (1)
Employer branding (2)
Employer resources (8)
Events (9462)
Executive appointments (32)
FDA (1947)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (83)
Gene editing (17)
Generative AI (2)
Gene therapy (48)
GLP-1 (109)
Government (232)
Grass and pollen (1)
Guidances (253)
Healthcare (2195)
HIV (14)
Huntington's disease (2)
IgA nephropathy (27)
Immunology and inflammation (28)
Immuno-oncology (6)
Indications (26)
Infectious disease (212)
Inflammatory bowel disease (19)
Inflation Reduction Act (2)
Influenza (11)
Intellectual property (18)
Interviews (5)
IPO (3608)
Job creations (147)
Job search strategy (34)
JPM (2)
Kidney cancer (7)
Labor market (8)
Layoffs (31)
Leadership (1)
Legal (395)
Liver cancer (9)
Longevity (1)
Lung cancer (100)
Lymphoma (81)
Machine learning (4)
Management (2)
Manufacturing (48)
MASH (23)
Medical device (1690)
Medtech (1697)
Mergers & acquisitions (1223)
Metabolic disorders (140)
mRNA (5)
Multiple sclerosis (17)
NASH (1)
Neurodegenerative disease (32)
Neuropsychiatric disorders (10)
Neuroscience (297)
NextGen: Class of 2026 (426)
Non-profit (265)
Now hiring (1)
Obesity (41)
Opinion (8)
Ovarian cancer (17)
Pain (14)
Pancreatic cancer (22)
Parkinson's disease (40)
Partnered (1)
Patents (32)
Patient recruitment (22)
Peanut (7)
People (2189)
Pharmaceutical (3)
Pharmacy benefit managers (4)
Phase 1 (1771)
Phase 2 (3053)
Phase 3 (3318)
Pipeline (1927)
Policy (8)
Postmarket research (346)
Preclinical (557)
Press Release (16)
Prostate cancer (20)
Psychedelics (1)
Radiopharmaceuticals (26)
Rare diseases (95)
Real estate (198)
Recruiting (6)
Regulatory (2130)
Reports (11)
Research institute (132)
Resumes & cover letters (1)
Rett syndrome (6)
RSV (16)
Schizophrenia (18)
Series A (8)
Series B (10)
Service/supplier (1)
Sickle cell disease (15)
Special edition (2)
Spinal muscular atrophy (8)
Sponsored (2)
Startups (125)
Stomach cancer (1)
Supply chain (8)
Tariffs (2)
Vaccines (84)
Venture capital (6)
Weight loss (25)
Women's health (17)
Date
Today (7)
Last 7 days (37)
Last 30 days (413)
Last 365 days (4423)
2026 (1120)
2025 (4511)
2024 (5190)
2023 (6111)
2022 (6895)
2021 (7045)
2020 (5971)
2019 (4493)
2018 (3342)
2017 (3174)
2016 (2541)
2015 (3037)
2014 (2024)
2013 (1282)
2012 (1541)
2011 (1806)
2010 (1718)
Location
Africa (39)
Alabama (6)
Alaska (1)
Arizona (27)
Asia (4055)
Australia (474)
California (1722)
Canada (414)
China (144)
Colorado (69)
Connecticut (74)
Delaware (71)
Europe (10337)
Florida (274)
Georgia (65)
Idaho (4)
Illinois (106)
India (6)
Indiana (103)
Japan (73)
Kansas (13)
Kentucky (15)
Louisiana (7)
Maine (20)
Maryland (211)
Massachusetts (1173)
Michigan (72)
Minnesota (103)
Missouri (21)
Montana (11)
Nebraska (7)
Nevada (12)
New Hampshire (11)
New Jersey (778)
New Mexico (1)
New York (635)
North Carolina (200)
North Dakota (1)
Northern California (946)
Ohio (28)
Oklahoma (1)
Pennsylvania (330)
South America (68)
Southern California (665)
Tennessee (25)
Texas (280)
United States (6627)
Utah (52)
Virginia (40)
Washington D.C. (15)
Washington State (208)
Wisconsin (13)
70,832 Results for "73".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
March 25, 2026
·
4 min read
Press Releases
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
February 25, 2026
·
8 min read
Press Releases
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
February 25, 2026
·
8 min read
Press Releases
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
March 5, 2026
·
11 min read
Vaccines
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.
March 23, 2026
·
2 min read
·
Heather McKenzie
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
March 9, 2026
·
2 min read
·
Heather McKenzie
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
December 22, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Compounding Pharmacies Market Size to Hit USD 33.73 Billion by 2034
June 23, 2025
·
1 min read
BioMidwest
CinRx Pharma Announces Additional $73 Million Financing
CinRx Pharma today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.
May 30, 2024
·
4 min read
Layoffs
Lyell Cuts 73 Employees as Part of LA Site Closure
After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma is closing its Los Angeles manufacturing facility, eliminating dozens of jobs there.
April 7, 2025
·
1 min read
·
Angela Gabriel
1 of 7,084
Next
